Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.59 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ESRRA | P11474 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11975687 | 0.86 | CYP1A2 (0.59) | CYP1A2CYP2A6TSHRGABRA1GABRB2 | |
| SCHEMBL8781825 | 0.85 | GABRA1 (0.48) | CYP1A2TSHRGABRA1GABRB2LMNA | |
| SCHEMBL30876294 | 0.85 | GABRA1 (0.48) | CYP1A2TSHRGABRA1GABRB2LMNA | |
| SCHEMBL29350027 | 0.78 | GABRA1 (0.42) | CYP1A2TSHRGABRA1GABRB2LMNA | |
| SCHEMBL29494605 | 0.77 | CYP2A6 (1.00) | CYP1A2CYP2A6TSHRNPC1RAB9A | |
| SCHEMBL2473555 | 0.77 | CYP2A6 (1.00) | CYP1A2CYP2A6TSHRNPC1RAB9A | |
| SCHEMBL25405851 | 0.77 | TP53 (0.47) | CYP1A2CYP2A6TSHRGABRA1LMNA | |
| SCHEMBL30381967 | 0.75 | GABRA1 (0.57) | CYP1A2CYP2A6TSHRKMT2ACYP2C19 | |
| SCHEMBL4657600 | 0.75 | GABRA1 (0.57) | CYP1A2CYP2A6TSHRKMT2ACYP2C19 | |
| SCHEMBL2487241 | 0.74 | GABRA1 (0.39) | CYP1A2TSHRGABRA1GABRB2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024891-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-01-27 | — | — | US | disclosed |
| US-20210221784-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | UNIVERSITÉ DE STRASBOURG (FR) | 2021-07-22 | — | — | US | disclosed |
| US-10005732-B2 | Potent non-urea inhibitors of soluble epoxide hydrolase | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005732-B2 | Potent non-urea inhibitors of soluble epoxide hydrolase | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-06-26 | — | — | US | disclosed |
| US-9951065-B2 | Benzimidazole and imadazopyridine carboximidamide compounds | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951065-B2 | Benzimidazole and imadazopyridine carboximidamide compounds | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9546156-B2 | N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
| US-20160280681-A1 | N-BICYCLIC ARYL,N'-PYRAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-09-29 | — | — | US | disclosed |
| US-9175285-B2 | Potent non-urea inhibitors of soluble epdxide hydrolase | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-11-03 | — | — | US | disclosed |
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-08-20 | — | — | US | disclosed |
| US-20080300269-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7429669-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429669-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080119538-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2008-01-17 | — | — | US | disclosed |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2008-01-17 | — | — | US | disclosed |
| US-20080015219-A1 | Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; acid-functional aryl substituted cyclopentanone or hydroxycyclopentane compounds | ALLERGAN, INC. | 2008-01-17 | — | — | US | disclosed |
| US-20070293561-A1 | 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists | ALLERGAN, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293561-A1 | 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists | ALLERGAN, INC. | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221784-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | ACHE, TRPV1, OPRL1 | CYP1A2 397/4885CYP2A6 662/4885TSHR 4694/4885 |
| US-20080300269-A1 | THERAPEUTIC COMPOUNDS | THPO, HLA-C, PIGO | CYP1A2 3277/4885CYP2A6 2658/4885TSHR 3352/4885 |
| US-20070293561-A1 | 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists | PTGIR, PTGIS, PTGER2 | CYP1A2 282/4885CYP2A6 594/4885TSHR 1079/4885 |
| US-20220024891-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | APC, VHL, KRAS | CYP1A2 3356/4885CYP2A6 2648/4885TSHR 3669/4885 |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | IDO1, IDO2, INMT | CYP1A2 162/4885CYP2A6 1231/4885TSHR 1752/4885 |
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | HTR6, HTR5A, HTR7 | CYP1A2 88/4885CYP2A6 26/4885TSHR 846/4885 |
| US-20080015219-A1 | Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; acid-functional aryl substituted cyclopentanone or hydroxycyclopentane compounds | PTGER2, PTGER1, PTGS2 | CYP1A2 177/4885CYP2A6 160/4885TSHR 2235/4885 |
| US-20160280681-A1 | N-BICYCLIC ARYL,N'-PYRAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | TK1, TNNI3K, CHUK | CYP1A2 2553/4885CYP2A6 3385/4885TSHR 368/4885 |
| US-20080119538-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, GOT1 | CYP1A2 1966/4885CYP2A6 1798/4885TSHR 4020/4885 |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, COXFA4L2 | CYP1A2 1375/4885CYP2A6 1657/4885TSHR 4392/4885 |
| US-10005732-B2 | Potent non-urea inhibitors of soluble epoxide hydrolase | EPHX1, EPHX2, ECE1 | CYP1A2 772/4885CYP2A6 810/4885TSHR 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.